Cognitive Longevity After 40: Build Your Baseline Before Chasing Biomarkers or Supplements

Cognitive longevity is the ability to preserve the mental functions that make everyday life work: attention, memory, planning, processing speed, language, and judgment. For adults over 40, the most useful question is not, "Which brain supplement should I take?" It is, "What can I measure, improve, and sustain across the systems that support my brain?"

That distinction matters because the current conversation mixes real advances in Alzheimer's biomarkers and treatments with claims that a single diet, peptide, or supplement can protect the brain. The evidence supports a more grounded approach: establish the foundations first, use clinical testing when there is a clinical reason, and treat novel interventions as experiments rather than insurance policies.

Cognitive longevity is a multi-system project

Alzheimer's disease is not the only pathway to cognitive decline. Vascular injury, hearing loss, depression, sleep disruption, social isolation, physical inactivity, smoking, diabetes, and traumatic brain injury can all matter. The 2024 Lancet Commission identified 14 modifiable risk factors across the life course and estimated that they account for about 45% of dementia cases at a population level. That is an estimate, not a promise that an individual can prevent dementia through perfect habits. Still, it is a useful reason to focus on the factors that are both measurable and actionable. Livingston et al., *The Lancet*, 2024

The practical implication is simple: cognitive longevity should resemble retirement saving more than a rescue mission. Small, repeatable deposits into cardiovascular fitness, blood-pressure care, sleep, strength, nutrition, and learning can begin well before a person has any symptoms.

Established evidence: build the four-part baseline

1. Treat vascular health as brain health

The brain depends on a dense, high-flow vascular system. High blood pressure is therefore not only a cardiovascular issue.

In SPRINT MIND, 9,361 adults aged 50 or older with hypertension were randomized to different systolic blood-pressure targets. Over a median 5.1 years, the more intensive-treatment group had a lower rate of mild cognitive impairment: 14.6 versus 18.3 cases per 1,000 person-years. The trial did not show a statistically significant reduction in probable dementia, so it should not be presented as a dementia-prevention guarantee. It does show why blood pressure deserves a place in a cognitive longevity plan. SPRINT MIND Investigators, *JAMA*, 2019

Observable markers:

• Home blood-pressure readings collected consistently, using a validated device and the method recommended by a clinician.
• Follow-up of elevated readings with a qualified healthcare professional.
• Smoking status, glucose markers, and lipid measures discussed in routine care when relevant.

Do not self-prescribe a blood-pressure target from a study. Medication choices, symptoms, kidney function, and other conditions change the calculation.

2. Train aerobic capacity and strength

Exercise is not a magic shield against neurodegeneration. It is, however, one of the most credible ways to improve the cardiovascular, metabolic, and functional conditions in which the brain operates.

The FINGER randomized trial tested a two-year package of diet, exercise, cognitive training, and vascular-risk monitoring in older adults at increased risk of cognitive decline. The intervention improved or maintained global cognitive performance better than the control condition. Crucially, it tested a package, not a single supplement or a single workout style. Ngandu et al., *The Lancet*, 201560461-5)

For a 40-plus adult, start with capacity, not intensity theater:

1. Schedule three aerobic sessions each week, beginning at a conversational pace if necessary.
2. Add two full-body strength sessions, prioritizing movements that train legs, pulling, pushing, carrying, and balance.
3. Increase duration, load, or pace gradually, while protecting sleep and recovery.
4. Keep a simple training log.

Observable markers:

• Weekly aerobic minutes completed.
• Strength exercises, loads, repetitions, and perceived difficulty.
• A repeatable walking route, cycling effort, or submaximal fitness test performed under similar conditions every 8 to 12 weeks.
• Fewer missed sessions, not heroic single sessions.

3. Protect sleep as a performance input

Sleep is often treated as optional until memory slips or daytime fatigue becomes disruptive. For cognitive longevity, it belongs in the baseline from day one.

Track the basics for two weeks: usual bedtime, wake time, estimated sleep duration, awakenings, alcohol intake, caffeine timing, and daytime sleepiness. A wearable can help reveal patterns, but it cannot diagnose sleep apnea or explain persistent cognitive symptoms. Loud snoring, witnessed breathing pauses, frequent morning headaches, or excessive daytime sleepiness deserve clinical attention.

The goal is not a perfect sleep score. It is a stable enough pattern that training, mood, attention, and recovery are not repeatedly undermined.

4. Keep learning effortful and social

Brain games may be enjoyable, but cognitive longevity is broader than an app score. Choose activities that require novelty, feedback, and sustained attention: learning a language, playing music with others, taking a demanding course, volunteering, or practicing a new technical skill.

The marker is not whether an activity feels "brainy." It is whether it remains challenging enough to require deliberate effort and whether you return to it consistently.

Emerging evidence: biomarkers can clarify symptoms, not replace a baseline

Blood biomarkers are a genuine advance. In a 2024 study of patients already undergoing evaluation for cognitive symptoms, a blood test combining p-tau217 with an amyloid ratio achieved 88% to 92% diagnostic accuracy for Alzheimer's pathology across four cohorts. This was a symptomatic clinical population, not a screening study for healthy 45-year-olds. Palmqvist et al., *JAMA*, 2024

That distinction is essential. A result can carry a different meaning when a person has symptoms, family history, anxiety, or a low underlying probability of disease. A blood test is information, not a diagnosis, prognosis, or personal action plan.

Anti-amyloid therapies also belong in the emerging, specialist-led category. In CLARITY AD, lecanemab modestly slowed clinical decline in people with early symptomatic Alzheimer's disease and confirmed amyloid pathology, while amyloid-related imaging abnormalities were more common in the treatment group. van Dyck et al., *New England Journal of Medicine*, 2023 These treatments are not wellness tools and do not replace prevention-oriented habits.

Personal experimentation: supplements need a higher bar

Personal experimentation can be reasonable when it is transparent, time-limited, and low-risk. It becomes a problem when a supplement is treated as a proven cognitive-longevity intervention because it affects an appealing mechanism.

NMN is a useful example. A small 2021 trial found that NMN increased muscle insulin sensitivity in prediabetic postmenopausal women. It did not test whether NMN prevents cognitive decline, treats Alzheimer's disease, or extends human lifespan. Yoshino et al., *Science*, 2021

If you choose to experiment, write down:

• The exact product, dose, and cost.
• The specific outcome you expect to change.
• A baseline measure collected before starting.
• A review date, usually 8 to 12 weeks later.
• Reasons to stop, including side effects or no meaningful benefit.

A supplement should not crowd out training, sleep, food quality, blood-pressure follow-up, or a clinical assessment when symptoms are present.

A 12-week cognitive longevity reset

Consider Maya, 52, who is worried because she occasionally loses words in stressful meetings. Instead of ordering a stack of nootropics, she starts with a baseline: two weeks of sleep notes, home blood-pressure measurements, a training log, and a short note on when the word-finding episodes occur.

Over 12 weeks, she walks or cycles three times weekly, strength-trains twice weekly, moves her final caffeine earlier, and restarts a weekly French conversation group. Her review is concrete: resting blood pressure trend, completed sessions, sleep regularity, energy, and whether the episodes persist or worsen. If they do, the next step is a clinician, not a larger supplement order.

Errors to avoid

• The single-cause error: assuming amyloid, insulin resistance, menopause, or one toxin explains every cognitive concern.
• The metric-confusion error: treating a wearable score or a blood biomarker as a diagnosis.
• The supplement-substitution error: spending attention and money on capsules while skipping movement, sleep, or vascular care.
• The all-or-nothing error: quitting after one missed week instead of returning to the next planned session.
• The delay error: normalizing persistent cognitive changes, major mood shifts, or sleep-breathing symptoms instead of discussing them with a clinician.

Cognitive longevity is not a promise of control over every form of brain aging. It is a disciplined way to improve the conditions that support cognition now, while leaving room for clinical science to do its proper job when it is needed.

Sources